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Abstract
BACKGROUND: Hyperthyroid patients commonly complain of
generalized bony aches, which are frequently overlooked due
to the more prominent symptoms of cardiovascular and ner-
vous disturbances. Hyperthyroid patients are expected to have
abnormal bone metabolism as part of the generalized hyper-
metabolic status.
The aim of this study is to verify the presence of metabolic bone
superscan in association with the hypermetabolic stats in vari-
ous groups of hyperthyroidism. Secondly, to correlate these
superscan features with the various laboratory results in hyper-
thyroid patients.
MATERIAL AND METHODS: Forty-five hyperthyroid patients
confirmed by clinical and laboratory results were enrolled in
this work. In all patients, a 99mTc-pertechnetate thyroid uptake
scan was acquired. On a different day, total body bone scan
was acquired three hours post IV injection of 555–925 MBq of
99mTc-MDP. Serum FT3, FT4, TSH, Ca++, alkaline phosphatase
(AP) and parathyroid hormone (PTH) were monitored in all pa-
tients as markers of thyroid and bone metabolism. Ten cases
with no thyroid diseases were included as a control group. Pa-
tients with thyroiditis or long history of antithyroid drugs for more
than one year were excluded from the study.
RESULTS: The patients were subdivided into three groups:
Graves’ disease (GD) (n = 30), toxic nodular goiter (TNG) (n =
= 10) and autonomous toxic adenoma (AT) (n = 5). The TSH
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for the whole group was significantly suppressed compared to
the control group with higher suppression in the Graves’ dis-
ease group than in the TNG or AT groups. 99mTc-pertechnetate
uptake values in the Graves' disease group were significantly
higher than the TNG and AT groups (p < 0.05).
Metabolic superscan (MSS) was noted in 90 % of the Graves'
cases, 20% in TNG and in none of the AT group. There were no
significant differences regarding Ca+, AP and PTH between
the Graves' and non-Graves’ groups (p > 0.05).
CONCLUSIONS: Disturbances in bone metabolism are more
prevalent in Graves' disease than in other types of hyperthy-
roidism. The addition of the bone scan to the diagnostic work
up of patients with Graves' disease is a sensitive indicator for
metabolic bone changes and could help in the future manage-
ment and follow up for this group of patients.
Keywords: hyperthyroidism, Graves’ disease, superscan,
bone scan, metabolic bone changes
Introduction
Hyperthyroidism is an autoimmune disease with a hypermet-
abolic state characterized by overproduction of thyroid hormones
due to hyper-functioning thyroid tissue. The main leading thyroid
pathologies are diffuse toxic hyperplasia (Graves’ disease — GD),
toxic multinodular goiter (TNG) and autonomous toxic adenoma
(AT). The pathophysiology of hyperthyroidism includes accelerat-
ed bone turnover in favour of bone resorption related to direct
stimulation of bone cells by the high levels of circulating thyroid
hormones. Thyroid hormones exert their effect on osteoblasts via
nuclear receptors to stimulate osteoclastic bone resorption. On
the other hand, correction of hyperthyroid status may result in
normalization of bone turnover [1–3].
Biomarkers for bone metabolism include bone formation (os-
teoblastic activity) or bone resorption (osteoclastic activity) and
are usually used to monitor metabolic changes in metabolic bone
diseases including hyperthyroidism. They have many limitations
including availability, cost, technical demand and multiplicity (no
single test is specific enough to give a definite answer for the
metabolic status of bone). In addition, these laboratory assays
suffer from a lack of standardization, cross reactivity, and differ-
ence in immunoassays and are influenced by gender, age, diur-
nal variation, and renal and liver diseases [4–8].
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Skeletal uptake of 99mTc-labelled diphosphonate depends pri-
marily upon osteoblastic activity and skeletal vascularity. As there
is direct coupling between bone resorption and formation; an
osteoblastic response follows osteoclastic activity in a coordi-
nated pattern leading to new bone formation. It is recognized
that bone-seeking radiopharmaceuticals are subject to rapid and
increased ionic exchange with the bone mineral at sites of new
bone formation, with particular affinity for areas where active
mineralization is occurring. The bone scan image therefore rep-
resents a functional display of the total skeletal metabolism and
has a potentially valuable role to play in the assessment of pa-
tients with metabolic bone disorders, including hyperthyroidism
[8, 9]. Accelerated bone turnover in patients with hyperthyroid-
ism is expected to produce metabolic superscan (MSS) features
in the bone scan images. These features may include increased
tracer uptake in the axial skeleton, long bones and peri-articular
areas with prominent calvaria. Other features are faint visualiza-
tion of kidneys, beading of costochondral junctions and neck tie
sternum. The frequency and severity of these features in bone
scans is directly proportional to the degree of accelerated bone
turnover [10–13].
These considerations, besides the limited literature about stud-
ies on the use of bone scanning to evaluate patients with hyper-
thyroidism, encouraged us to perform the current prospective
study. The objectives are, firstly, to verify the presence of meta-
bolic superscan features in various groups of hyperthyroidism and,
secondly, to correlate the superscan features with the available
laboratory results in hyperthyroid patients.
Material and methods
Patients
The current prospective study involved fifty-five subjects who
were enrolled into two separate groups. The first group com-
prised forty-five patients diagnosed with hyperthyroidism by both
clinical and laboratory results. The second group comprised ten
subjects with no thyroid illness who were considered as a con-
trol group. All subjects were seen at the nuclear medicine de-
partment of the National Cancer Institute during the period from
December 2003 to November 2005. The study was discussed
and approved by the ethical committee of the National Cancer
Institute in Cairo University. Informed consent with a complete
description of the procedures was signed by all patients and/or
their relatives. The median age for the hyperthyroid patients was
37 years (range 22–52 years) compared to 35 years (range 30–
–40 years) for control cases. The prevalence of hyperthyroidism
was greater in females, with a female:male ratio of 3:1. This gen-
der ratio was the same in the control cases as well. The exclu-
sion criteria were patients with a history of thyroiditis or long his-
tory of anti-thyroid medication (more than one year). In addition,
patients taking oral contraceptives, calcium supplements, vita-
min D or other medication that might affect bone metabolism
were excluded. No cases were post-menopausal or had evidence
of hepatic or renal disorders.
Methods
The laboratory assessment of thyroid functional status was
based on chemo-luminescence assay of FT3, FT4 and TSH, in
addition to the biochemical markers for bone metabolism that in-
cluded serum calcium (Ca++), alkaline phosphatase (ALP) and
parathyroid hormone (PTH) levels.
The scintigraphic part of the study incorporated the perfor-
mance of 99mTc thyroid scans with uptake and 99mTc-99m MDP
whole body bone scanning in two separate settings for all 55
subjects. The gamma camera used for scintigraphic imaging
was a dual-head Siemens e-cam equipped with a parallel hole
all-purpose collimator. The first study invloved the thyroid scan
with uptake performed 20 minutes following IV administration of
185 MBq of 99mTc-Pertechnetate. The subjects were positioned
supinely with hyper-extended neck, and the acquisition was car-
ried out in the anterior view using a matrix size of 128 ¥ 128 for
two minutes. Thyroid uptake was quantified automatically after
correction for background activity according to the provided
software program. Additional detailed anterior view using a ma-
trix size of 256 ¥ 256 with 1.5 zooming was taken for 1500 k
counts per image. 57Cobalt point-source marker was used to iden-
tify the suprasternal notch.
On a different day 99mTc-MDP whole body bone scanning was
performed 2–4 hours following IV administration of 555–925 MBq
of 99mTc-MDP. The acquisition was carried out in the anterior and
posterior views simultaneously with the aid of 180 configuration of
the two heads of the Gamma camera. The matrix used was 256 ¥
¥ 1028 with a table speed at 10–12 cm/minute.
Statistical analysis
Results for laboratory tests and thyroid uptake were expressed
as means ± SD unless otherwise indicated. Differences between
groups were analyzed using Mann-Whitney U test for assessment
of differences between mean values. p < 0.05 was considered
significant.
Results
According to hormonal profile and thyroid scan findings, the
studied patients were subdivided into Graves’ disease (GD) (n =
= 30), toxic nodular goiter (TNG) (n = 10) and autonomous toxic
adenoma (AT) (n = 5). The basic clinical demographic data for
these groups and the control subjects are presented in Table 1.
Table 1. Patient characteristics
GD TNG AT Controls
Number 30 10 5 10
Age: range (Median) 22–42 (32) 42–52 (47) 30–40 (35) 30–40 (35)
Female: male ratio 3:1 2.8:1 1.5 :1 3:1
GD — Graves’ disease; TNG — toxic nodular goiter; AT — autonomous toxic adenoma
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The TSH for the whole group was 0.005 IU ± 0.003 IU which
was significantly suppressed compared to the control group with
1.7 IU ± 0.5 IU (p < 0.001). The TSH values for the Graves’ dis-
ease group were 0.003 IU ± 0.001 IU, TNG group 0.005 IU ±
± 0.002 and the AT group 0.007 ± 0.002 IU with no significant
differences between the groups (p > 0.05). The FT3 and FT4 val-
ues for the GD group were higher than those for the TNG and AT
groups, as shown in Table 2. However, the difference was not
statistically significant (p > 0.05). On the other hand, there were
clear differences between the control group FT3 and FT4 levels
compared to all the hyperthyroid groups (Table 2).
Analysis of the metabolic biomarkers showed normal results
for all subjects studied (Table 2). The ALP was slightly elevated
in the GD group compared to the rest of the groups but the dif-
ference was not statistically significant. Ca++ and PTH levels
were comparable in all the studied hyperthyroid and control
groups.
Scintigraphic findings
99mTc-thyroid scan with uptake
 The qualitative interpretation for the 99mTc-Pertechnetate thy-
roid scan was essential in defining the different subgroups. Fea-
tures suggestive of Graves' disease included dense homoge-
nous diffuse uptake in both lobes, while those for TNG included
multiple nodules with more than one prominently hot nodule. AT
is characterized by a single large toxic nodule with suppression
of the rest of the gland in most cases. The uptake values for all
of the hyperthyroid groups were 18% ± 8%, which was signifi-
cantly higher than the control group at 2.5% ± 1% (p < 0.001).
Quantitatively, the thyroid uptake value made it possible to dif-
ferentiate between the various hyperthyroid groups, especially
in defining the Graves’ group. Table 3 illustrates that the uptake
for the Graves’ group (24% ± 4 %) was significantly higher than
the TNG and AT groups (15% ±5% and 10% ± 2% respectively)
(p < 0.05 for both).
99mTc-MDP bone scintigraphy
Interpretation of the bone scans was done by two experienced
nuclear medicine physicians. Six criteria were set for the diagno-
sis of MSS, namely:
— prominent uptake in calvarium;
— prominent uptake in sternum;
— increased bone/soft tissue ratio;
— faint visualization of kidneys;
— prominent uptake in appendicular skeleton;
— beaded costal ends.
The presence of more than three of these criteria was consid-
ered diagnostic for metabolic superscan.
Metabolic superscan features were present in 27 out of the 30
patients with GD (90%). This was higher than the rest of the hy-
perthyroid groups as only two patients (20%) of the TNG group
exhibited MSS features (p < 0.01) and none from the AT group
had any significant MSS features (p < 0.001). The bone scan
features in the control group were normal with no pathological
findings (Table 3).
A correlation between the high level of thyroid uptake and MSS
was found only in GD but not in the rest of the hyperthyroid pa-
tients. Figures 1A, 1B, 2A and 2B show MSS patterns in patients
with GD while Figures 3A and 3B show bone scans lacking MSS
in the other groups of hyperthyroidism.
Discussion
Hyperthyroidism, a clinical syndrome characterized by mani-
festations of excess thyroid hormone, is a commonly recognized
condition of the thyroid gland. It affects bone metabolism and is
thought to be an under-recognized but important cause of os-
teoporosis [14]. Hyperthyroidism accelerates bone turnover and
shortens the normal bone remodelling cycle [15, 16].
Osteoporosis is a major public health problem in which there
is a disturbance in the osteoblastic and osteoclastic activities with
a predominance of bone resorption resulting in accelerated bone
turnover. Thyroid hormones are known to exert direct effects on
Table 2. Thyroid hormonal profile and metabolic biomarkers in hyperthyroid groups and control subjects
GD TNG AT Controls p*
Ft3 (n. 1.8–4.2 pg/ml) 8.7  ± 1.5% 8.2 ± 1 8 ± 0.5 2.2 ± 0.2 0.001
Ft4 (n. 0.8–1.2 pg/ml) 6.5 ± 1.2 5.5 ± 0.9 5 ± 0.8 1 ± 0.2 0.001
TSH (n. 0.4–4 Mu/ml) 0.003 ± 0.001 0.005 ± 0.002 0.007 ± 0.002 1.7 ± 0.3 0.001
Calcium (n. 8.4–10.4 U/L) 8.7 ± 0.6 8.4 ± 0.4 8.2 ± 0.2 8.5 ± 0.5 NS
ALP (n. 53–128 U/L) 100 ± 20 85 ± 25 80 ± 20 88 ± 40 NS
PTH (n. 7–70 pg/ml) 22 ± 10 20 ± 8 20 ± 5 20 ± 4 NS
p* — is for the difference between the hyperthyroid groups and the control group; GD — Graves’ disease; TNG — toxic nodular goiter; AT — autonomous toxic adenoma;
N — normal value; NS — non-significant; ALP — alkaline phosphatase; PTH — parathormone
Table 3. Thyroid uptake and metabolic superscan in hyperthyroid groups and control subjects
GD TNG AT Controls p*
Thyroid uptake (N.0.4–4%) 24 ± 4% 15 ± 5% 10 ± 2% 2.5 ± 1% 0.001
MSS 27/30 (90%) 2/10 (20%) 0/5 (0%) 0/10 (0%) 0.001
p* — is for the difference between the hyperthyroid groups and the control group; GD — Graves’ disease; TNG — toxic nodular goiter; AT — autonomous toxic adenoma;
MSS — metabolic superscan
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bone formation and resorption, and the excess thyroid hormones
leads to a net loss of bone and hence reduction in bone mineral
density (BMD) [17].
On the other hand, it is reported that correction of hyperthy-
roid status may result in normalization of bone turnover [1–3].
Recently, the effects of anti-thyroid therapy on hyperthyroid pa-
tients' skeletons have been addressed due to the increasing world-
wide interest in the prevention of osteoporosis [1, 18].
Our prospective study has shown that accelerated bone turn-
over, as explored by MSS features on bone scans, were signifi-
cantly higher in the GD group (90%) compared to the TNG group
(20%) and AT (0%) hyperthyroid patients. In addition, we found
that no correlation existing between FT3, FT4 & TSH levels and
the superscan features as there were no significant differences in
the levels of these hormones among the variable groups of hy-
perthyroid patients. In contrast, reasonable correlation was found
between the thyroid uptake level by scintigraphy and the super-
scan features in GD patients that were significantly high compared
to TNG & AT. There is also agreement between our data and se-
veral other studies which have shown reduced bone mineral mea-
surements in hyperthyroid patients [19, 20]. Auwerx et al. showed
a 13% reduction in lumbar spine bone mineral using dual-photon
absorptiometry [20]. Similarly, Kung et al. showed significantly
lower BMDs in lumbar spine and femoral neck (0.75 ± 0.15 vs.
0.92 ± 0.16 g/cm2, p < 0.005; 0.62 ± 0.12 vs. 0.70 ± 0.12 g/cm2,
p < 0.01) in TSH suppressed patients after Iodine-131 ablation
for thyroid cancer when compared with an age and sex matched
control group [21].
Hyperthyroidism causes acceleration of bone remodelling, and
even though it is one of the known risk factors for osteoporosis,
the metabolic effects of thyroid hormones on bone is a little-dis-
cussed subject [15].
On the basis of the previous studies showing that hyperthy-
roidism has a detrimental effect on bone mass or is associated
with fractures [19, 22], we hypothesize that accelerated bone
turnover that results in MSS features may occur at an earlier
stage as part of generalized hypermetabolic status of hyper-
thyroidism.
Figure 1. 40-year-old male patient has severe hyperthyroidism attributed to Graves' disease. A. 99mTc- thyroid scan and uptake shows diffuse intense
thyroid uptake [thyroid uptake = 22.8 (normal: 0.5–4%)]. B. 99mTc-MDP bone scan performed 2 weeks post I-131 therapy shows MSS features with
residual intense intra-thyroidal I-131 activity.
Figure 2. 35-year-old female patient has active GD. A. 99mTc-thyroid scan shows diffuse intense thyroid uptake with suppressed back-ground activity. The
uptake was 21% (normal: 05-4%). B. 99mTc-MDP bone scan showing MSS.
          A B
          A  B
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To our knowledge, there is limited data in the literature that
focuses on the assessment of bone turnover using MSS fea-
tures in various groups of hyperthyroidism or that correlates these
MSS features with various laboratory results in hyperthyroid pa-
tients. Our demonstration of higher bone turnover denoted by
superscan features in GD compared to TNG and AT patients,
despite similar levels of thyroid hormone profiles, can be ex-
plained by mechanisms other than the effect of thyroid hormones
on bone turnover, particularly in GD. This opinion is enforced by
the fact that high bone turnover may continue despite normal-
ization of FT3 and FT4 in TSH suppressed GD patients. Serum
thyrotropin releasing autoantibody (TRAb), which is a triggering
factor in the pathogenesis of GD, might directly affect bone me-
tabolism independently of thyroid function. Recent reports which
demonstrate that osteoblasts possess functional TSH receptors
strongly support this opinion about TRAb [2, 23, 24]. Therefore,
it is possible that abnormal bone metabolism in GD is partially
explained by the interaction of TRAb with TSH receptors in the
osteoblasts.
In contrast to other results, this work could not demonstrate
a correlation between laboratory bone biomarkers including se-
rum calcium, thyroid and parathyroid hormones. This finding can
be explained by the differences in patient populations. In the cur-
rent work the patients had newly diagnosed hyperthyroidism with
severe symptoms. Moreover, the differences in the types and du-
ration of the given anti-thyroid medications may account for the
differences between the present study results and other investi-
gations, as hyperthyroidism may increase the degradation rate of
these biomarkers, shortening their half-life [3, 25–27].
The limitations of this study include the inability to assess oth-
er biomarkers such as bone-specific alkaline phosphatase and
C-terminal propeptide of type I procollagen for bone formation
and serum C-telopeptide and urinary N-telopeptide cross links for
bone resorption as well as TRAb, which are not done routinely in
our institute. Secondly, this study was carried out on a short-term
basis without follow-up. However, the strengths of this study in-
clude its novel prospective nature in addressing the clinical use-
fulness of bone scans, especially MSS features, in patients with
hyperthyroidism. Secondly, the study is conducted in various
groups of hyperthyroidism patients who have comparable sex ratio
and age range compared to control subjects.
Conclusion
The disturbance of bone metabolism in hyperthyroid patients
is strongly evident in GD but not in TNG or AT. Metabolic super-
scan features were significantly better than biomarkers in the ex-
ploration of high bone turnover in hyperthyroid patients and par-
ticularly in GD. Importantly, the integration of bone scanning in
the diagnostic work up for GD patients can be a sensitive indica-
tor for metabolic bone changes that should be of real help in fu-
ture patient management and follow up to identify Graves' pa-
tients who are at high-risk of osteoporosis and pathological frac-
tures. Further studies are recommended to compare bone scan
findings and particularly MSS features, with more specific bio-
markers of bone metabolism as well as assaying TRAb in Graves‘
patients before therapy and during follow up.
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